

Bevacizumab gamma for treating wet age-related macular degeneration

Information for the public

Published: 4 December 2024

www.nice.org.uk

Bevacizumab gamma (Lytenava) is available on the NHS. It is a possible treatment for wet age-related macular degeneration (AMD) in adults if, in the eye being treated:

- the best-corrected visual acuity (the ability to see detail at a distance) is between 6/12 and 6/96
- there is no permanent structural damage to the central fovea (the part of the eye that helps people to see things in sharp detail)
- the area affected by AMD is not bigger than 12 times the size of the optic disc (the part of the eye where the optic nerve connects to the retina)
- there are signs that the condition has been getting worse.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on AMD](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Macular Society](#), 0300 3030 111
- [RNIB](#), 0303 123 9999

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6660-8